Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Chief Financial Officer | February 18, 2023 | February 22, 2023 |
| Translate Bio, Inc.TBIO · Entity 135439 | Chief Financial Officer | September 14, 2021 | September 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date February 18, 2023 · Filed February 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 5,072 |
Ending reported balance
After 2023-02-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-18 · Exercise / conversion · Acquired 3,825 · Balance 6,464 F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Row 2 · 2023-02-21 · Tax withholding · Disposed 1,392 · Balance 5,072 F2: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,475 |
Reported balance
After 2023-02-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-02-18 · Exercise / conversion · Disposed 3,825 · Balance 11,475 F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.
Translate Bio, Inc.
Report date September 14, 2021 · Filed September 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stcok Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.23 · Expires 2031-04-18 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-14 · Sale · Disposed 201,800 · Balance 0 F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F2: This option was granted on April 19, 2021. The shares underlying this option are scheduled to vest over four years, with 25% of the shares vesting on April 19, 2022 and the remainder vesting in equal monthly installments through April 19, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
F2: This option was granted on April 19, 2021. The shares underlying this option are scheduled to vest over four years, with 25% of the shares vesting on April 19, 2022 and the remainder vesting in equal monthly installments through April 19, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2023 Filed Feb 22, 2023 22:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 1,392 | $48.26 | $67,177.92 |
DisclosureSEC source: 0001209191-23-011790 · doc4.xml · nonDerivative · entry 2 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,072 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 22:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 3,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-011790 · doc4.xml · derivative · entry 3 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,475 Underlying: Common Shares · 3,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. F3 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 22:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-011790 · doc4.xml · nonDerivative · entry 1 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 21:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 1,111 | $55.76 | $61,949.36 |
DisclosureSEC source: 0001209191-22-053989 · doc4.xml · nonDerivative · entry 2 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,639 F3 · kind: On October 14, 2021, the reporting person was granted 15,000 restricted stock units. On October 14, 2022, 3,750 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 21:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-053989 · doc4.xml · derivative · entry 3 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Shares · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · derivative.exercise_date: The restriced stock units shall vest as follows: (i) one quarter of the shares shall vest on October 14, 2022, (ii) one quarter of the shares shall vest on October 14, 2023, (iii) one quarter of the shares shall vest on October 14, 2024, and (iv) one quarter of the shares shall vest on October 14, 2025. F1 · derivative.expiration_date: The restriced stock units shall vest as follows: (i) one quarter of the shares shall vest on October 14, 2022, (ii) one quarter of the shares shall vest on October 14, 2023, (iii) one quarter of the shares shall vest on October 14, 2024, and (iv) one quarter of the shares shall vest on October 14, 2025. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 21:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-053989 · doc4.xml · nonDerivative · entry 1 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restriced stock units shall vest as follows: (i) one quarter of the shares shall vest on October 14, 2022, (ii) one quarter of the shares shall vest on October 14, 2023, (iii) one quarter of the shares shall vest on October 14, 2024, and (iv) one quarter of the shares shall vest on October 14, 2025. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| October 07, 2022 Filed Oct 12, 2022 21:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $61.65 | $0.00 |
DisclosureSEC source: 0001209191-22-053498 · doc4.xml · derivative · entry 1 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Shares · 14,000 shares Expires 2032-10-07 F1 · derivative.exercise_date: This option was granted on October 7, 2022 with respect to 14,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 7, 2022. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 21:39 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046714 · doc4.xml · derivative · entry 1 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest in full on February 16, 2025, subject to continued service to the Company or any of its subsidiaries. F2 · derivative.expiration_date: The restricted stock units shall vest in full on February 16, 2025, subject to continued service to the Company or any of its subsidiaries. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 15,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-011841 · doc4.xml · derivative · entry 2 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,300 Underlying: Common Shares · 15,300 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. F3 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $58.29 | $0.00 |
DisclosureSEC source: 0001209191-22-011841 · doc4.xml · derivative · entry 1 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2032-02-18 F1 · derivative.exercise_date: This option was granted on February 18, 2022 with respect to 30,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of March 18, 2022. Read SEC document |
| October 14, 2021 Filed Oct 19, 2021 00:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $98.70 | $0.00 |
DisclosureSEC source: 0001209191-21-060777 · doc4.xml · derivative · entry 2 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Shares · 90,000 shares Expires 2031-10-14 F3 · derivative.exercise_date: This option was granted on October 14, 2021 with respect to 90,000 Common Shares, with 25% of the shares vesting on October 14, 2022 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months. Read SEC document |
| October 14, 2021 Filed Oct 19, 2021 00:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060777 · doc4.xml · derivative · entry 1 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: This restricted stock unit award was granted on October 14, 2021 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on October 14, 2022, (ii) one quarter of the shares vesting on October 14, 2023, (iii) one quarter of the shares vesting on October 14, 2024, and (iv) one quarter of the shares vesting on October 14, 2025. F2 · derivative.expiration_date: This restricted stock unit award was granted on October 14, 2021 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on October 14, 2022, (ii) one quarter of the shares vesting on October 14, 2023, (iii) one quarter of the shares vesting on October 14, 2024, and (iv) one quarter of the shares vesting on October 14, 2025. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 19:33 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStcok Option (right to buy) · Derivative | 201,800 | $0.00 Strike: $19.23 | $0.00 |
DisclosureSEC source: 0001209191-21-056064 · doc4.xml · derivative · entry 1 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 201,800 shares Expires 2031-04-18 F1 · kind: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F2 · derivative.exercise_date: This option was granted on April 19, 2021. The shares underlying this option are scheduled to vest over four years, with 25% of the shares vesting on April 19, 2022 and the remainder vesting in equal monthly installments through April 19, 2025. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 16:49 UTC | Translate Bio, Inc. TBIO · Entity 135439 | GrantStock Option (Right to Buy) · Derivative | 201,800 | $0.00 Strike: $19.23 | $0.00 |
DisclosureSEC source: 0000899243-21-016406 · doc4.xml · derivative · entry 1 Smith Brendan · CIK 0001857492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,800 Underlying: Common Stock · 201,800 shares Expires 2031-04-18 F1 · derivative.exercise_date: This option was granted on April 19 2021. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on April 19, 2022 and the remainder vesting in equal monthly installments through April 19, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.